Promethazine (PMZ) is the antimotion sickness drug of choice in the U.S. Space Shuttle program; however, virtually nothing is known about the bioavailability and performance effects of this drug in the microgravity environment. PMZ has detrimental side effects on human performance on Earth that could affect Shuttle operations. In a recent ground-based study we examined: 1) the effects of promethazine (PMZ) on Shuttle landing performance using the portable inflight landing operations trainer (PILOT), and 2) saliva and urine samples to determine the pharmacokinetics of PMZ. The PILOT performance data is presented here.


    Access

    Access via TIB

    Check availability in my library


    Export, share and cite



    Title :

    Effects of Promethazine on Performance During Simulated Shuttle Landings


    Contributors:
    Harm, D. L. (author) / Putcha, L. (author) / Sekula, B. K. (author) / Berens, K. L. (author)


    Publication date :

    1999-01-01


    Type of media :

    Conference paper


    Type of material :

    No indication


    Language :

    English